Megestrol Acetate for Prevention of Weight Loss During Modern Radiotherapy in Patients With Head and Neck Cancer: A Multicenter Randomized Controlled Trial
BACKGROUND: Weight loss is a common complication during radiotherapy for head and neck cancer and may adversely affect treatment tolerance and outcomes. We evaluated whether megestrol acetate (MA) prevents treatment-related weight loss. METHODS: In this multicenter, open-label randomized controlled trial, 102 patients with non-nasopharyngeal head and neck squamous cell carcinoma undergoing radiotherapy were assigned to MA plus standard care or standard care alone. Standard care consisted of nutritional counseling, symptom management, and feeding-tube placement when clinically indicated. The primary endpoint was change in body weight from baseline to 6 weeks post-radiotherapy. RESULTS: At 6 weeks post-radiotherapy, the MA group showed a mean weight gain of 2.07 kg, whereas the control group lost 1.74 kg (p < 0.01). Weight gain was primarily due to increased fat mass, with no significant difference in muscle mass. Quality of life was similar between groups. CONCLUSION: MA improved weight preservation during radiotherapy and may serve as an adjunct to supportive care in head and neck cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: TCTR20240330005.
Authors
- Vatanyu Samakgarn
- Pooriwat Muangwong (ORCID: https://orcid.org/0000-0002-3366-6146)
- Imjai Chitapanarux (ORCID: https://orcid.org/0000-0002-8552-0149)
- Piyapasara Toapichattrakul (ORCID: https://orcid.org/0000-0002-0988-8988)
- Panlop Malasri
Institutions
- Ministry of Public Health (TH)
- Lampang Cancer Hospital (TH)
- Udon Thani Hospital (TH)
- Chiang Mai University (TH)
Publication Details
- Journal
- Head & Neck
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/hed.70558
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00